pharmacokinetic data were modeled using a nonparametric methodology and with a nonlinear 23 pharmacokinetic structural model. The extent and consequences of pharmacokinetic variability were 24 explored using Monte Carlo simulation. The relationship between drug exposure and clinical 25 response was explored using logistic regression. Optimal sampling times were identified using D-26 optimal design. The fit of the nonlinear model was acceptable. Data from the healthy volunteers 27 Voriconazole is an orally bioavailable triazole with potent activity against a range of 37 medically important fungal pathogens. Voriconazole is a first-line agent for the treatment of invasive 38 aspergillosis (12), disseminated candidiasis (8) and invasive infections caused by less common fungal 39 pathogens (5). Recent studies suggest that voriconazole can be used for the prevention of invasive 40 fungal infections in immunocompromised patients (6, 13). Despite extensive clinical trial data, there 41 is a persistent debate relating to issues surrounding the optimal clinical use of voriconazole. 42
Population pharmacokinetics provides a summary of the pharmacokinetic behavior in patient 43 populations and is a critical tool for the identification of a range of strategies that may be important 44 for the optimal clinical use of voriconazole. 45
There has been a progressive understanding of the relationship between voriconazole drug 46 exposure and clinical outcome. Studies in a number of disparate populations and settings consistently 47 allude to clinically relevant exposure-effect and exposure-toxicity relationships . In some studies 48 these relationships have been quantified using a range of modeling techniques (7, 9, 11). The 49 pharmacokinetics of voriconazole are known to be highly inherently variable. Voriconazole also 50 exhibits nonlinear (Michaelis-Menten) pharmacokinetic behavior, which represents a challenge for 51 precise dosage adjustment in clinical settings, and the consistent achievement of systemic drug 52 concentrations that are therapeutic and non-toxic. 53
This study describes the population pharmacokinetics of voriconazole in adults. The 54 populations of interest include patients with invasive aspergillosis that were enrolled in a Phase III 55 clinical trial (2) and healthy volunteers studied in the early phases of drug development. The latter 56 were included to buttress the relatively sparse data obtained from patients, and to enable robust 57 estimates for the two parameters that describe nonlinear pharmacokinetics (Vmax and Km). This 58 population pharmacokinetic model will enable further exploration of exposure-response relationships, 59
on September 12, 2017 by guest http://aac.asm.org/ Downloaded from 7 concomitant oral and i.v. input. Equations 1, 2 and 3 describe the rate of change of the amount of 109 voriconazole in the gut, central compartment and peripheral compartment, respectively. The data 110
were weighted by the inverse of the estimated assay variance. The fit of the model to the data was 111 assessed using the log likelihood ratio, mean weighted error (a measure of bias) and bias-adjusted 112 mean weighted squared error (a measure of precision). A visual inspection and the coefficient of 113 determination of a linear regression of the observed-versus-predicted values was also performed. The currently licensed i.v. regimen of 6 mg/kg i.v. for 2 dosages followed by 4 mg/kg i.v Q12H was 121 used for the simulations. The absolute dosage of voriconazole was calculated using the mean weight 122 of the study population. A series of 5,000-patient simulations were performed. Both normal and log-123 normal parameter distributions were explored and distinguished on their ability to recapitulate the 124 parameter values of the starting population. For oral dosing, the inter-subject variability in 125 bioavailability (F) was incorporated into the simulations via the output equations. The AUC 0-12 was 126 calculated using integration. 127
128

Statistical Methods 129
Differences in the Bayesian estimates parameter values between healthy volunteers and 130 patients were compared using a Mann-Whitney test (SYSTAT version 11). Logistic regression was 131 used to investigate the relationship between drug exposure and the response to voriconazole at the end 132 of treatment (SYSTAT version 11). The latter was determined using the global assessment by the 
Optimal Sampling 140
To provide a further insight into the portions of the dosing interval that are information rich in 141 terms of obtaining blood samples to delineate pharmacokinetic parameter estimates. The method 142 originally described by Tam and Drusano (10) was used. The multiple model file from the output of 143 BIG NPAG was generated. This file contains a summary of the "support points" and their associated 144 probabilities that describes the behavior of voriconazole in the volunteer and patient population. 145
Using the SAMPLE module of ADAPT 5 (1), a standard intravenous voriconazole regimen (6 mg/kg 146 for two dosages followed by 4 mg/kg) was "administered" to each support point. statistically different (see Figure 4) . Most notably the volume of patients tended to be much higher 183 compared with healthy volunteers. Moreover, the parameter estimates in patients were more variable 184 than those of healthy volunteers. 185
The original parameter values and their dispersions were recapitulated using Monte Carlo 186 simulation. The trough concentrations after the first week for patients receiving oral (400 mg Q12H 187 for two dosages followed by 200 mg Q12H) and i.v. therapy (6 mg/kg Q12H for two dosages 188 followed by 4 mg Q12H) for 1 week are shown in Figure 5 In comparison to many anti-infective agents, the pharmacokinetics of voriconazole are 209 relatively well characterized. Somewhat surprisingly, however, there are no population 210 pharmacokinetic models for adult patients. Two models have been developed for children (3, 7) and 211 these have been important to identify optimal dosing strategies in this population. The absence of 212 models for adults primarily relates to the absence of robust pharmacokinetic data from patients with 213 invasive fungal infections. A further obstacle has been the inherently variable pharmacokinetics of 214 voriconazole. This agent is well known to exhibit Michaelis-Menten (nonlinear) pharmacokinetics, 215 which is related to saturable clearance mechanisms. Robust population PK models represent an 216 important step for the optimal use of voriconazole in critically ill patients. 217
A robust estimate of the degree of nonlinearity in individual patients and/or populations 218 requires the use of more than one dosage-a single fixed regimen may not enable the extent of 219 nonlinearity to be accurately estimated. While a degree of variation in absolute dosage is achieved 220 using weight-based i.v. dosing, the variations in dosage may not be large enough to trigger and 221 therefore describe non-linear pharmacokinetics. In the current analyses, this problem was 222 circumvented by co-modeling a rich dataset from healthy volunteers in whom a range of dosages had 223 been studied and for some of whom dosage escalation had also been performed. This approach 224 provided rich information that enabled robust estimates to be obtained for Vmax and Km, which are 225 the two parameters describing nonlinear clearance. A potential disadvantage of this approach is the 226 mixing of populations (i.e. healthy volunteers and patients) who may handle drug differently. 227
Nevertheless, in the absence of informative data from patients this is a necessary first step and 228 provides a foundation for the future studies that are required to further characterize the 229
pharmacokinetics of voriconazole. 230
The fit of the model to the data was acceptable. The population pharmacokinetic model 231 enables the well recognized and clinically relevant inter-patient variability to be quantified. throughout these analyses-it is evident in the estimates for coefficient of variation for some of the 237 parameters, the Monte Carlo simulations, the Bayesian estimates for the parameter values and the 238 optimal sampling times. The overall estimate for bioavailability (86%) is higher than other studies in 239 children (3, 7), but lower than previously described in healthy volunteers. Similarly, the estimate for 240 Km (2.07 mg/L) in this study is lower than has been previously described in children (range 3.03-7.84 241 mg/L; (3, 7)), consistent with the observation that pharmacokinetics of voriconazole in adults are 242 more likely to be nonlinear than in children. The reasons for the extent of observed pharmacokinetic 243 variability in this study are not readily apparent (i.e. the pharmacokinetic variability is not accounted 244 for by covariates). While the CYP2C19 genotype clearly has an impact upon the clearance of 245 voriconazole, this information was not available for the patients in this study (14) . The greater extent 246 of pharmacokinetic variability in patients compared with healthy volunteers (see Figure 4) likely 247 reflects a degree a range of factors such as physiological derangement, drug-drug interactions and 248 altered gut motility. 249
One advantage of population pharmacokinetic modeling is the ability to obtain estimates for 250 population pharmacokinetic parameter values for individual patients using relatively sparse data. 251
These parameter values can be used to describe the behavior of a drug in that individual and to 252 estimate measures of drug exposure such as the trough concentration and AUC 0-12 . Unlike previous 253 studies, we did not observe any relationship between drug exposure at the end of the first week and 254 the ultimate clinical outcome. There are a number of possible explanations for this: (1) the sample 255 size is relatively small for patients with a syndrome whose ultimate outcome is affected by many 256 factors; and (2) all patients in this study initially received i.v. therapy, which produced drug exposures 257 that were probably associated with near maximal antifungal effect (there were only 7/43 patients with 258 trough concentrations < 1mg/L at the end of the first week-see Figure 2) . Further research is required to address how this can be achieved in a timely and optimally precise 267 manner. The Monte Carlo simulations also highlight the potential peril of using oral dosing as initial 268 therapy. If an initial oral regimen is deemed appropriate on clinical grounds, an oral loading dosage 269
should be used and consideration given to therapeutic drug monitoring. 270
This study contains the first description of optimal sampling times that are maximally 271 informative and that facilitate the further description of voriconazole pharmacokinetics. In busy 272 clinical settings, the best sampling strategy remains unclear, but the following are relevant: (1) a 273 single trough concentration is very difficult to interpret because some patients whose serum 274 concentrations are persistently greater than Km will rapidly accumulate drug and are at increased risk 275 of developing toxicity; (2) the best dosing interval for sampling is uncertain, but a reasonable 276 approach is to sample at the end of day 2 and then again in the first week of therapy; (3) a distinction 277 should be made between drawing samples to optimize therapy (e.g. ensuring trough concentrations are 278 within a pre-specified range) and drawing samples to enable the pharmacokinetics of an individual 279 patient to be described. The latter is a more challenging problem because of the nonlinear 280 pharmacokinetics of voriconazole. If robust estimates of Km and Vmax in an individual patients are 281 required then a range of dosages must be studied (i.e. an attempt must be made to trigger nonlinear 282 pharmacokinetics in that patient). Obviously, this may be difficult to achieve in a patient with a life-283 threatening infection. The optimal sampling histogram also highlights the difficulties in sampling 284 strategies to ensure that the pharmacokinetics are adequately described in a population receiving an 285 inherently variable compound. Here, there is a tension between obtaining enough samples to ensure 286 Ka is the first-order rate constant that connects the gut with the central compartment; Vmax is the 361 maximum rate of clearance of voriconazole; Km is the concentration of voriconazole where clearance 362 is half maximal; Kcp and Kpc are the first-order inter-compartmental rate constants connecting the 363 central and peripheral compartments; F is the bioavailability and Lag is the absorption time. 
